Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2020-04-21 / J Transl Med 2020 04;18(1):176Curcumin effect on cancer cells‘ multidrug resistance: An update
/in Curcuma, International Publications /von 2020-04-19 / Phytother Res 2020 Apr;Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial
/in Curcuma, International Publications /von 2020-04-18 / Phytomedicine 2020 Apr;70:153218Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment
/in Dendritic Cells, International Publications /von 2020-04-07 / Clin Transl Oncol 2020 Apr;A moderate thermal dose is sufficient for effective free and TSL based thermochemotherapy
/in Hyperthermia, International Publications /von 2020-04-02 / Adv Drug Deliv Rev 2020;163-164:145-156Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 conventional dendritic cells
/in Dendritic Cells, International Publications /von 2020-04-01 / J Immunother Cancer 2020 Apr;8(1)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution